Navigation Links
GeneLink Reports Second Quarter Improvement
Date:8/18/2010

ORLANDO, Fla., Aug. 18 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading applied genomics biotech company, reported financial results for the fiscal quarter ended June 30, 2010.

Financial Highlights:

  • Continued progress towards profitability: Quarterly operating loss reduced by 35% over Q2 2009
  • Comparable quarter gross profit improvement of 10% over Q2 2009
  • Six Month Revenues of $4,240,177 compared to $4,085,215 in the first six months of 2009

Gary Beeman, GeneLink's CEO stated, "In the first half of 2010, the Company continued to develop its position as the leader in genetically customized nutritional and personal care wellness solutions.  The second quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins. Operating losses decreased by 35% and gross margin improved 10% as compared to the prior year.   GeneLink continues to focus its efforts on expansion of its current sales base while extending its sales and product offerings to new strategic and catalytic channels compatible with current initiatives."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "In addition to the progress made within GeneLink during the second quarter, the past six months confirm what GeneLink has known for over a decade -- that genetic knowledge can be utilized to make almost any personal product more effective.  With key additions to executive management in first half of 2010, GeneLink is equipped to continue to develop our science, add new products, expand sales channels and execute our strategic plan."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in applied genomics. GeneLink's patented and patent pending technologies include proprietary genetic assessments and specific DNA tests used to guide the formulation and delivery of personalized health, beauty and wellness products. For more information visit www.genelinkbio.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Research and Markets has announced the addition of ... Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... current Positron Emission Tomography (PET) scanner and cyclotron install base ... France , Germany , ... and the United Kingdom . Along with ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Systemic Lupus Erythematosus Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Europe Systemic Lupus Erythematosus Market and Competitive ... into Systemic Lupus Erythematosus pipeline products, Systemic ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... TransWipe Volume 3 is a set of 30 professional ... TransWipe preset between two video clips to instantly add a unique transition to any ... customizable color and orientation options. TransWipe Volume 3 is a Final Cut Pro X ...
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , the ... and with egg freezing, today announced the grand opening of its first location ... care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Derrin Doty Group ... families of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring ... year local girl who died suddenly due to complications from the flu, that they ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the ... challenges in getting employees to understand and use the free preventive care benefits available ... leading non-profit business groups of large, self-insured public and private employers, MBGH found that ...
Breaking Medicine News(10 mins):